If one is looking for beta within the healthcare arena, the best option obviously is biotech. On the chart below it shows that October during the last 5 years has been by far the softest month for the XBI. Now one can look at this with a glass half full of half empty. One should scope out best in breed stocks which may get somewhat affected if the falling tide causes them to weaken. If investors shy away from the possible opportunities that present themselves, then they are not doing it correctly. SGEN could be about to bust above a 188.09 cup base trigger. MRTX on a move back toward the 150 level may be another event to take advantage. NVTA back toward the round 40 number. There will be a myriad of chances to pick your spots as rhetoric will heat up with presidential debates about to take place. The fact that some of these leaders are acting well in the face of inflated “drug prices”, political uncertainties and possible seasonality headwinds speaks volumes. Are you listening?